Vericiguat belongs to the class of sGC-stimulating drugs like riociguat, the first of the drugs in this class to have been approved for clinical use in patients with pulmonary arterial hypertension (PAH) [24]. This evidence concerns the gene SGCB and pulmonary arterial hypertension.